Effects of DaxibotulinumtoxinA for Blepharospasm & Hemifacial Spasm

Status Not yet recruiting

Clinical Trial Summary

The goal of this clinical trial is to test the effects of DaxibotulinumtoxinA-Lanm (Daxxify) in patients with benign essential blepharospasms (BEB) and hemifacial spasms (HFS). The main questions to answer: 1. Is there clinically significant difference (measured by Jankovic Rating Scale (JRS) score from base to peak efficacy) for patients with BEB and HFS treated with Daxxify? 2. What percentage of patients achieve a clinical response? Participants historically treated with Botox for either BEB or HFS will be crossed over to Daxxify treatment in order to serve as their own control and examine the efficacy of Daxxify.

Clinical Trial Description

This will be a single-arm, crossover study, in which each patient is their own historical control using a 2:1 conversion ratio of Daxxify to Botox units. Study participants will be selected through the electronic medical records of ophthalmologists at Montefiore Medical Center. Medical documentation on each patient will include information on age, sex, race, Benign Essential Blepharospasm (BEB) diagnosis year and duration, Hemifacial Spasms (HFS) diagnosis year and duration, and past treatments. The immediate effects (desired or undesired) of Daxxify observed within 48-72 hours, will be defined as (1) complete relief of spasms (2) partial relief to a tolerable level (3) mild to moderate ocular irritation (4) ptosis. Overall efficacy will be evaluated using the base to peak efficacy (recorded in changes to Jankovic Rating Scale (JRS) scores) and be defined as (1) excellent (resolution of signs and symptoms, only requiring injections > 5-6 months (2) moderate (improvement in signs and symptoms but requiring repeated injections within < 5 months (3) poor (no improvement in signs and symptoms). Adverse side effects will be documented, and Daxxify will be discontinued in any patients who develop significant side effects that outweigh the benefits. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT06195241
Study type	Interventional
Source	Montefiore Medical Center
Contact	Ricky Paramo, BS
Phone	718-920-2020
Email	rickyparamo@gmail.com
Status	Not yet recruiting
Phase	Phase 4
Start date	April 2024
Completion date	April 2026

View Details

See also
Status	Clinical Trial	Phase
Not yet recruiting	`NCT04474977` - Microvascular Decompressive Surgery for Hemifacial Spasm
Withdrawn	`NCT01932255` - CSF Leak Following Microvascular Decompression: the Benefit of Routine Postoperative Lumbar Tap	N/A
Completed	`NCT00210431` - Post Marketing Surveillance Study of Dysport
Recruiting	`NCT03306940` - Botulinum Toxin A in the Treatment of Hemifacial Spasm	N/A
Completed	`NCT05103202` - Efficacy and Safety of 10-Week or Shorter vs 12-Week or Longer Injection Intervals of Botulinum Toxin
Unknown status	`NCT01726725` - Hemifacial Spasm and Desflurane	N/A
Completed	`NCT01598961` - Determination of Target of Adequate Partial Neuromuscular Blockade for Electrophysiologic Monitoring During Microvascular Decompression Surgery	N/A
Not yet recruiting	`NCT04589364` - Study of Abobotulinum Toxin Versus Neubotulinum Toxin Injection For Hemifacial Spasm in Thai Patients	Phase 3
Completed	`NCT01613781` - Determination of Target of Adequate Partial Neuromuscular Blockade for Electrophysiologic Monitoring During Microvascular Decompression Surgery	N/A
Completed	`NCT03508882` - Pretarsal Versus Preseptal Botulinum Toxin for Patients With Eyelid Spasm	Phase 4
Enrolling by invitation	`NCT01271634` - Observe Abnormal Potential From the Offending Vessel to the Facial Muscles of HFS Patients	N/A
Recruiting	`NCT04645277` - Magnetic Resonance Imaging Study on Patients With Hemifacial Spasm
Completed	`NCT03390803` - Effect of Hemifacial Spasm on Intraocular Pressure Measurement	N/A
Completed	`NCT01728428` - A Multicenter, Observational Study to Evaluate Clinical Manifestation, Diagnosis and Treatment of Primary Hemifacial Spasm in Chinese Patients	N/A
Completed	`NCT04621578` - Transcutaneous Electrical Acupoint Stimulation on Postoperative Dizziness in Hemifacial Spasm Patients	N/A
Completed	`NCT00276315` - Assessment of Effectiveness and Safety of Dysport® for the Treatment of Hemifacial Spasm	Phase 3
Completed	`NCT02761096` - Effect of Acupuncture on Inflammation and Immune Function After Craniotomy	N/A
Not yet recruiting	`NCT01546805` - Testing the Effect of Zinc Supplementation to Improve the Treatment Effect of Botulinum Toxin for Oculofacial Spasm	N/A
Unknown status	`NCT01564979` - Effect on Tear Functions of Pretarsal and Preseptal Techniques of Botulinum Toxin Type A Injection in Hemifacial Spasm	Phase 2
Completed	`NCT01168388` - Movement Disorder Survey in East China	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Effects of DaxibotulinumtoxinA for Blepharospasm and Hemifacial Spasm

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms